Medical Neurogenetics, LLC Sustainability Profile
Medical Neurogenetics, LLC, headquartered in the United States, is a pioneering entity in the field of neurogenetics, focusing on the intersection of genetics and neurological disorders. Founded in 2015, the company has rapidly established itself as a leader in genetic testing and analysis, particularly for conditions such as epilepsy, neurodegenerative diseases, and developmental disorders. With a commitment to advancing personalised medicine, Medical Neurogenetics offers a range of innovative services, including comprehensive genetic testing and consultation. Their unique approach combines cutting-edge technology with expert interpretation, ensuring accurate and actionable insights for healthcare providers and patients alike. Recognised for its contributions to the neurogenetics landscape, the company continues to expand its operational reach across major regions in the US, solidifying its position as a trusted partner in the medical community.
DitchCarbon Score
How does Medical Neurogenetics, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medical Neurogenetics, LLC's score of 64 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medical Neurogenetics, LLC, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Labcorp Holdings Inc., which may influence its climate commitments and reporting practices. While there are no documented reduction targets or climate pledges specific to Medical Neurogenetics, LLC, it is important to note that any potential climate initiatives or targets would likely be aligned with those of Labcorp Holdings Inc. This parent company has established various sustainability initiatives, which may include commitments to reduce emissions and improve environmental performance. As of now, Medical Neurogenetics, LLC does not have publicly available information regarding its own emissions or specific climate commitments. The absence of data suggests that the company may still be in the process of developing its sustainability strategy or reporting framework.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 69,115,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 178,899,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Medical Neurogenetics, LLC's Industry?
How Carbon Intensive is Medical Neurogenetics, LLC's Location?
Medical Neurogenetics, LLC's Scope 3 Categories Breakdown
Medical Neurogenetics, LLC's Scope 3 emissions, which decreased by 4% last year and increased by approximately 10% since 2020, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 76% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 54% of Scope 3 emissions.
Top Scope 3 Categories
Medical Neurogenetics, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medical Neurogenetics, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
